<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02665754</url>
  </required_header>
  <id_info>
    <org_study_id>GBIRB2016-002</org_study_id>
    <nct_id>NCT02665754</nct_id>
  </id_info>
  <brief_title>Intralymphatic Immunotherapy for House Dust Mite, Dog, and Cat Allergy Using Tyrosine S® in Allergic Rhinitis</brief_title>
  <acronym>ILIT-T</acronym>
  <official_title>The Efficacy and Adverse Effect of Intralymphatic Immunotherapy With Tyrosine S®, Allergen Extract for Immunotherapy, in Patients With Allergic Rhinitis Induced by House Dust Mite, Dog, and Cat Allergen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gachon University Gil Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will perform double-blinded placebo-controlled randomized clinical trial
      which evaluates the efficacy and safety of allergen-specific intralymphatic immunotherapy
      (ILIT) for allergens including Dermatophagoides farinae (Df), Dermatophagoides pteronyssinus
      (Dp), cat, and dog that are sensitized and provoke rhinitis-related symptoms in patients with
      allergic rhinitis (AR), using allergen extracts for allergen-specific immunotherapy (Tyrosine
      S, Allergy Therapeutic, West Sussex, UK).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After informed consent, subjects will be randomly assigned to ILIT group or placebo group in
      double-blind manner. In both group, causal allergen or placebo will be injected into inguinal
      lymph node through guidance by ultrasonography three times with 4-week interval. In ILIT
      group, initial dose of allergen will be 1,000-fold diluted solution from maximal
      concentration of allergen extract for subcutaneous immunotherapy (Tyrosine S, Allergy
      Therapeutic, West Sussex, UK) in volume of 0.1ml. If skin is highly reactive in skin prick
      test, the initial dose will be 10-fold dilution from maximal concentration where diameter of
      wheal is less than that of histamine. After the first dose, allergen concentration will be
      escalated 3-fold at second dose, and 10-fold at third dose if there are no (or mild) local or
      systemic hypersensitivity reaction. The allergen concentration will not change at second or
      third dose if there is moderate local or systemic reaction. The allergen concentration will
      decrease by 10 or 100-fold from previous concentration or further injection will be held if
      there is severe local or systemic reaction after sufficient explanation and discussion with
      subjects.

      The investigators will evaluate allergic rhinitis symptom score before and 4, 12 months after
      the initial treatment. Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) and
      Sino-Nasal Outcome Test (SNOT-20) will be used. Visual analogue scale (VAS) of symptoms
      including rhinorrhea, sneezing, nasal obstruction, postnasal drip, eye/nose/ear/palate
      itching, dyspnea, wheezing, chest discomfort as well as urticaria, angioedema, and itching on
      exposed skin during exposure to causal allergen in daily life will be also evaluated. Skin
      prick test (SPT), intradermal test (IDT), blood sampling for serum total immunoglobulin E
      (IgE), allergen-specific IgE, and allergen-specific immunoglobulin G4 (IgG4), nasal lavage
      for Th1, Th2, and Treg cytokines, and nasal provocation test (NPT) with Df and/or Dp allergen
      (in subjects whose AR symptoms are provoked by Df and/or Dp) will be also performed before
      and 4, 12 months after the initial treatment. In addition, the investigators evaluated the
      change of subjects' recognition of causal allergens, their avoidance, and AIT during this
      study. Using VAS, subjects were requested to score the rate of agreement with &quot;Allergen
      provokes allergic symptoms in daily life&quot;, &quot;Allergen avoidance can reduce allergic symptoms&quot;,
      &quot;Allergen-specific Immunotherapy (AIT) can reduce allergic symptoms&quot;, &quot;I can pay 50,000
      Korean Won (KRW)/month for allergen avoidance&quot;, &quot;I can pay 100,000 KRW/month for allergen
      avoidance&quot;, &quot;I can pay 200,000 KRW/month for allergen avoidance&quot;, &quot;I can pay 150,000 KRW for
      each injection of ILIT&quot;, &quot;I can pay 300,000 KRW for each injection of ILIT&quot;, &quot;I can pay
      600,000 KRW for each injection of ILIT&quot; before and after SPT/IDT, after NPT, 4 months and 1
      year after ILIT.

      Adverse events will be recorded and graded according to Muller classification and Ring and
      Meissner classification.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RQLQ</measure>
    <time_frame>4 months after the day of first injection of ILIT</time_frame>
    <description>Rhinoconjunctivitis Quality of Life Questionnaires</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SNOT-20</measure>
    <time_frame>before and 4, 12 months after the day of first injection of ILIT</time_frame>
    <description>Sinonasal Outcome Test-20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allergic symptoms provoked by causal allergen in daily life</measure>
    <time_frame>before and 4, 12 months after the day of first injection of ILIT</time_frame>
    <description>Rates scored by subjects using visual analogue scale regarding allergic symptoms provoked by causal allergen in daily life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhinitis symptom in nasal provocation test</measure>
    <time_frame>before and 4, 12 months after the day of first injection of ILIT</time_frame>
    <description>Rhinitis symptom (visual analogue scale: 0~100) during nasal provocation test with allergen of D. farinae and/or D. pteronyssinus in subjects in whom D. farinae and/or D. pteronyssinus is causal allergen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin reactivity in skin prick test</measure>
    <time_frame>before and 4, 12 months after the day of first injection of ILIT</time_frame>
    <description>Mean diameters of wheal caused by 1- to 10^7- fold dilution of causal allergen in skin prick test and their allergen histamine ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin reactivity in intradermal test</measure>
    <time_frame>before and 4, 12 months after the day of first injection of ILIT</time_frame>
    <description>Mean diameters of wheal caused by 10^2- to 10^7- fold dilution of causal allergen in intradermal test and their allergen saline ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total IgE level</measure>
    <time_frame>before and 4, 12 months after the day of first injection of ILIT</time_frame>
    <description>Serum total IgE level using ImmunoCAP (Thermo Fisher Scientific, Uppsala, Sweden)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allergen-specific IgE for causal allergen</measure>
    <time_frame>before and 4, 12 months after the day of first injection of ILIT</time_frame>
    <description>Allergen-specific IgE for causal allergen of D. farinae, D. pteronyssinus, cat, and/dog using ImmunoCAP (Thermo Fisher Scientific, Uppsala, Sweden)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines in nasal lavage fluid before and after nasal provocation test</measure>
    <time_frame>before and 4, 12 months after the day of first injection of ILIT</time_frame>
    <description>Cytokines of Th1, Th2, and Treg immunity including interleukin-4 (IL-4), IL-5, IL-10, IL-12, IL-13, interferon-gamma (IFN-g), and tumor growth factor-beta (TGF-b) in nasal lavage fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects' score (0~100) regarding agreement to &quot;Allergen provokes allergic symptoms in daily life&quot;</measure>
    <time_frame>before skin prick test / intradermal test, nasal provocation test, and 4, 12 months after the day of first injection of ILIT</time_frame>
    <description>Subjects' score regarding agreement to &quot;Allergen provokes allergic symptoms in daily life&quot; using visual analogue scale (0~100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects' score (0~100) regarding agreement to &quot;Allergen avoidance can reduce allergic symptoms&quot;</measure>
    <time_frame>before skin prick test / intradermal test, nasal provocation test, and 4, 12 months after the day of first injection of ILIT</time_frame>
    <description>Subjects' score regarding agreement to &quot;Allergen avoidance can reduce allergic symptoms&quot; using visual analogue scale (0~100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects' score (0~100) regarding agreement to &quot;Allergen-specific immunotherapy can reduce allergic symptoms&quot;</measure>
    <time_frame>before skin prick test / intradermal test, nasal provocation test, and 4, 12 months after the day of first injection of ILIT</time_frame>
    <description>Subjects' score regarding agreement to &quot;Allergen-specific immunotherapy can reduce allergic symptoms&quot; using visual analogue scale (0~100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Willingness to pay for allergen avoidance</measure>
    <time_frame>before skin prick test / intradermal test, nasal provocation test, and 4, 12 months after the day of first injection of ILIT</time_frame>
    <description>Agreement% scored by subjects using visual analogue scale to &quot;I am willing to pay 50,000, 100,000 or 200,000 Korean Won per month for allergen avoidance&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Willingness to pay for intralymphatic immunotherapy</measure>
    <time_frame>before skin prick test / intradermal test, nasal provocation test, and 4, 12 months after the day of first injection of ILIT</time_frame>
    <description>Agreement% scored by subjects using visual analogue scale to &quot;I am willing to pay 150,000, 300,000 or 600,000 Korean Won for each injection of intralymphatic immunotherapy&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal mucosal inflammation</measure>
    <time_frame>before and 4, 12 months after the day of first injection of ILIT</time_frame>
    <description>Inflammatory cell count in nasal mucosal biopsy (/high power field, x400)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RQLQ</measure>
    <time_frame>12 months after the day of first injection of ILIT</time_frame>
    <description>Rhinoconjunctivitis Quality of Life Questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal cavitary volume decrease in nasal provocation test</measure>
    <time_frame>before and 4, 12 months after the day of first injection of ILIT</time_frame>
    <description>Nasal cavitary volume decrease (basal%) measured by acoustic rhinometry during nasal provocation test with allergen of D. farinae and/or D. pteronyssinus in subjects in whom D. farinae and/or D. pteronyssinus is causal allergen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allergen-specific IgG4 for causal allergen</measure>
    <time_frame>before and 4, 12 months after the day of first injection of ILIT</time_frame>
    <description>Allergen-specific IgG4 for causal allergen of D. farinae, D. pteronyssinus, cat, and/dog using ImmunoCAP (Thermo Fisher Scientific, Uppsala, Sweden)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Active group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In active group, extract of causal allergen will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In placebo group, normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ILIT with extract of causal allergen</intervention_name>
    <description>0.5 ml of allergen extract from D. farinae, D. pteronyssinus, cat, and/or dog for allergen specific immunotherapy (Tyrosine S, Allergy Therapeutic, UK) will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.</description>
    <arm_group_label>Active group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ILIT with normal saline</intervention_name>
    <description>0.5 ml of normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rescue medication for allergic rhinitis</intervention_name>
    <description>Subjects are requested to administer oral antihistamine (cetirizine) or nasal glucocorticosteroid (ciclesonide) as rescue medication for allergic rhinitis in accordance with severity and frequency of allergic rhinitis symptoms according to Allergic Rhinitis and its Impact on Asthma (ARIA) guideline.</description>
    <arm_group_label>Active group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        We enrolled subjects who suffered from AR, symptoms of which were provoked by Dp, Df, dog,
        and/or cat allergen. Concretely, two inclusion criteria should be met.

          1. Sensitization should be verified by skin prick test and the level of serum specific
             IgE measured by ImmunoCAP® (Thermo Fisher Scientific, Uppsala, Sweden).

          2. Subjects should complain of AR symptoms during exposure of house dust, dog and/or cat
             in daily life.

        Exclusion Criteria:

          1. Uncontrolled or severe asthma according to Global Initiative of Asthma (GINA)
             guideline including a case in which forced expiratory volume in 1 s (FEV1) was less
             than 50% of predicted value

          2. Significant cardiovascular, hepatic, renal, hematologic, oncologic, or infectious
             diseases

          3. Administration of beta blocker, angiotensin converting enzyme inhibitor, tricyclic
             antidepressant, immunosuppressant including systemic glucocorticosteroid within last 2
             weeks

          4. AR caused by other perennial or seasonal allergen

          5. Prior history of allergen-specific immunotherapy

          6. Rejection or low compliance,

          7. Pregnancy or lactation

          8. Vulnerable volunteer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Min Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang Min Lee, MD, PhD</last_name>
    <phone>82-10-2639-1253</phone>
    <email>sangminlee77@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sang Pyo Lee, MD, PhD</last_name>
    <phone>82-10-3422-7373</phone>
    <email>allergy21@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Min Lee, M.D., Ph.D.</last_name>
      <phone>82-10-2639-1253</phone>
      <phone_ext>82-32-460-8930</phone_ext>
      <email>sangminlee77@naver.com</email>
    </contact>
    <contact_backup>
      <last_name>Sang Pyo Lee, M.D., Ph.D.</last_name>
      <phone>82-10-3422-7373</phone>
      <phone_ext>82-32-460-8203</phone_ext>
      <email>allergy21@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Senti G, Johansen P, Kündig TM. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol. 2009 Dec;9(6):537-43. doi: 10.1097/ACI.0b013e3283310ff7. Review.</citation>
    <PMID>19680119</PMID>
  </reference>
  <reference>
    <citation>Senti G, Johansen P, Kündig TM. Intralymphatic immunotherapy: from the rationale to human applications. Curr Top Microbiol Immunol. 2011;352:71-84. doi: 10.1007/82_2011_133. Review.</citation>
    <PMID>21725898</PMID>
  </reference>
  <reference>
    <citation>Kündig TM, Johansen P, Bachmann MF, Cardell LO, Senti G. Intralymphatic immunotherapy: time interval between injections is essential. J Allergy Clin Immunol. 2014 Mar;133(3):930-1. doi: 10.1016/j.jaci.2013.11.036. Epub 2014 Jan 15.</citation>
    <PMID>24439076</PMID>
  </reference>
  <reference>
    <citation>Johansen P, Kündig TM. Intralymphatic immunotherapy and vaccination in mice. J Vis Exp. 2014 Feb 2;(84):e51031. doi: 10.3791/51031.</citation>
    <PMID>24513675</PMID>
  </reference>
  <reference>
    <citation>Graf N, Dinkel B, Rose H, Hothorn LA, Gerhard D, Johansen P, Kundig TM, Klimek L, Senti G. A critical appraisal of analyzing nasal provocation test results in allergen immunotherapy trials. Rhinology. 2014 Jun;52(2):137-41. doi: 10.4193/Rhin.</citation>
    <PMID>24932625</PMID>
  </reference>
  <reference>
    <citation>Zaleska A, Eiwegger T, Soyer O, van de Veen W, Rhyner C, Soyka MB, Bekpen C, Demiröz D, Treis A, Söllner S, Palomares O, Kwok WW, Rose H, Senti G, Kündig TM, Ozoren N, Jutel M, Akdis CA, Crameri R, Akdis M. Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine. Allergy. 2014 Sep;69(9):1162-70. doi: 10.1111/all.12461. Epub 2014 Jul 12. Erratum in: Allergy. 2016 Jan;71(1):129.</citation>
    <PMID>24934402</PMID>
  </reference>
  <reference>
    <citation>Senti G, Kündig TM. Intralymphatic immunotherapy. World Allergy Organ J. 2015 Mar 7;8(1):9. doi: 10.1186/s40413-014-0047-7. eCollection 2015.</citation>
    <PMID>25780493</PMID>
  </reference>
  <reference>
    <citation>Hjálmsdóttir Á, Wäckerle-Men Y, Duda A, Kündig TM, Johansen P. Dosing intervals in intralymphatic immunotherapy. Clin Exp Allergy. 2016 Mar;46(3):504-7. doi: 10.1111/cea.12657.</citation>
    <PMID>26470052</PMID>
  </reference>
  <results_reference>
    <citation>Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ, Simard JJ, Wüthrich B, Crameri R, Graf N, Johansen P, Kündig TM. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17908-12. doi: 10.1073/pnas.0803725105. Epub 2008 Nov 10.</citation>
    <PMID>19001265</PMID>
  </results_reference>
  <results_reference>
    <citation>Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N, Steiner M, Hothorn LA, Grönlund H, Tivig C, Zaleska A, Soyer O, van Hage M, Akdis CA, Akdis M, Rose H, Kündig TM. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012 May;129(5):1290-6. doi: 10.1016/j.jaci.2012.02.026. Epub 2012 Mar 30.</citation>
    <PMID>22464647</PMID>
  </results_reference>
  <results_reference>
    <citation>Hylander T, Latif L, Petersson-Westin U, Cardell LO. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol. 2013 Feb;131(2):412-20. doi: 10.1016/j.jaci.2012.10.056.</citation>
    <PMID>23374268</PMID>
  </results_reference>
  <results_reference>
    <citation>Witten M, Malling HJ, Blom L, Poulsen BC, Poulsen LK. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol. 2013 Nov;132(5):1248-1252.e5. doi: 10.1016/j.jaci.2013.07.033. Epub 2013 Sep 13.</citation>
    <PMID>24035151</PMID>
  </results_reference>
  <results_reference>
    <citation>Patterson AM, Bonny AE, Shiels WE 2nd, Erwin EA. Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2016 Feb;116(2):168-70. doi: 10.1016/j.anai.2015.11.010. Epub 2015 Dec 17.</citation>
    <PMID>26706294</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2016</study_first_submitted>
  <study_first_submitted_qc>January 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2016</study_first_posted>
  <last_update_submitted>October 15, 2017</last_update_submitted>
  <last_update_submitted_qc>October 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gachon University Gil Medical Center</investigator_affiliation>
    <investigator_full_name>Sang Min Lee</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Allergic rhinitis</keyword>
  <keyword>Injection, intralymphatic</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Dermatophagoides farinae</keyword>
  <keyword>Dermatophagoides pteronyssinus</keyword>
  <keyword>Dogs</keyword>
  <keyword>Cats</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

